Kristine M. Ball joined Soteria in 2020, bringing over 25 years’ experience in the life-sciences industry. Most recently, Ms. Ball served as Senior Vice President of Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc. from 2017 through Menlo’s merger with Foamix, Inc. in March 2020. At Menlo, Ms. Ball was responsible for leading…
Dr. Zachary B. Hill, PhD, is co-founder and CSO of Soteria Biotherapeutics. In this role, he oversees the company’s discovery research activities and leads scientific strategy. Prior to founding Soteria, Dr. Hill was a postdoctoral fellow at UCSF, where he co-invented Soteria’s LITE Switch technology. While at UCSF he was a Helen Hay Whitney Fellow,…
Proceeds to fund early pipeline of novel switchable bispecific T-cell engagers to treat solid tumor cancers Company’s proprietary T-LITE platform based on small molecule-dependent activation of T-cell engagers, enabling potentially safer and more efficacious tumor targeted therapy Seasoned leadership to steer company’s growth and pipeline development SAN FRANCISCO, CA; May 17, 2021 – Soteria Biotherapeutics,…
Preeminent Leaders in Antibody and Cancer Immunotherapy Discovery and Development to Advise Company’s Early Pipeline Development SAN FRANCISCO, CA; November 12, 2020 – Soteria Biotherapeutics, Inc. (“Soteria”), a privately-held, immuno-oncology company focused on developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors, today announced the formation…
